Who Owns Arrowhead Pharmaceuticals Inc
Every manager with more than $100m in listed equities files a 13F each quarter naming what they hold. These are the ones reporting a position in Arrowhead Pharmaceuticals Inc.
Who crossed 5% of ARWR →Positions as of 2026-09-30
Largest first. The move is against the previous quarter that manager filed, not the previous calendar quarter.
| Manager | Value |
|---|---|
| Farther Finance Advisors, LLCStock12.1K shadded | $795K |
| Financial Enhancement Group LLCCOM4.9K shtrimmed | $301.3K |
| GAMMA Investing LLCCommon Stock4.5K shadded | $297.3K |
| MassMutual Private Wealth & Trust, FSBCommon / Ordinary Stock320 shtrimmed | $20.9K |
| Grove Bank & TrustCOM172 shheld | $11.3K |
| Marquette Asset Management, LLCCOM25 shheld | $1.6K |
| Retirement Wealth Solutions LLCCOM24 shtrimmed | $1.6K |
Source: quarterly 13F filings, via EDGAR. A 13F reports positions by CUSIP alone; each CUSIP here has been confirmed against OpenFIGI rather than matched by name, because a name match would attribute one company's shareholders to another. Positions are as of quarter end and can be months old by the time they are filed, and 13F covers long equity positions only — not shorts, and not most debt. The summed value is what these filers reported, not the company's institutional ownership.
More on ARWR
Follow Arrowhead Pharmaceuticals Inc (ARWR) by email
New trades in Arrowhead Pharmaceuticals Inc (ARWR) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.